Scientific Abstracts from the Phoenix Children’s 13th Annual Fetal Cardiology Symposium December 8–11, 2022 at The Phoenician, Scottsdale, AZ

View full-text article in PMC

. 2023 Mar 2;44(Suppl 1):1–5. doi: 10.1007/s00246-023-03110-3

Table: Outcomes of prenatal antiarrhythmic treatment of the ≥ 35-week fetus with supraventricular arrhythmia (SVA).

DX	Gestational Age at Presentation (wks)	Time to Convert (days)	Gestational Age at Delivery (wks)	NSVD (n = 23)	CS OB Reasons (n = 9)	CS Arrhythmia (n = 5)	Postnatal SVA (57%)
Short RP (n = 20)	36.1 ± 0.95	3.85 ± 3.92	38.4 ± 1.14	15/20 75%	3/9 33%	2/5 40%	13/20 65%
Long RP (n = 7)	36.2 ± 1.61	5.71 ± 5.50	38.5 ± 1.10	3/7 43%	3/9 33%	1/5 20%	5/7 71%
Flutter (n = 10)	36.2 ± 1.27	3.25 ± 5.57	38.3 ± 0.95	5/10 50%	3/9 33%	2/5 40%	3/10 30%

Gestational Age at Presentation
(wks)

Time to Convert
(days)

Gestational Age at Delivery
(wks)

NSVD
(n = 23)

CS OB Reasons
(n = 9)

CS
Arrhythmia
(n = 5)

Postnatal SVA
(57%)

Short RP

(n = 20)

36.1 ± 0.95

3.85 ± 3.92

38.4 ± 1.14

15/20

75%

3/9

33%

2/5

40%

13/20

65%

Long RP

(n = 7)

36.2 ± 1.61

5.71 ± 5.50

38.5 ± 1.10

3/7

43%

3/9

33%

1/5

20%

5/7

71%

Flutter

(n = 10)

36.2 ± 1.27

3.25 ± 5.57

38.3 ± 0.95

5/10

50%

3/9

33%

2/5

40%

3/10

30%

IUFD intrauterine fetal demise, VIP voluntary interruption of pregnancy, PVFR-VTI pulmonary vein forward/reverse velocity time integral